The widely preferred radioisotope ‘technetium-99’ is majorly fuelling global nuclear medicine radioisotopes market growth. Fact.MR’s market report reveals key market dynamics.
Rockville, Jan. 24, 2023 (GLOBE NEWSWIRE) — As per a new industry analysis by Fact.MR, a market research and competitive intelligence provider, the global nuclear medicine radioisotopes market is valued at US$ 8.82 billion in 2023 and is predicted to reach US$ 19.04 billion by the end of 2033.
Medical radioisotopes are harmless radioactive compounds that are typically employed in the diagnosis of medical disorders. These radioisotopes release gamma rays that are powerful enough to escape the body when they are used to diagnose a disease.
Dales of nuclear medicine radioisotopes are expected to rise rapidly during the forecast period due to the increasing rate of cancer cases and growing public knowledge of nuclear therapies. A radiopharmaceutical is a pharmaceutical formulation containing radioactive isotopes used in diagnosis and treatment. They are small, straightforward radioactive compounds used to treat cancer, heart and neurological diseases.
Download a Free Sample Copy of this Report – https://www.factmr.com/connectus/sample?flag=S&rep_id=8311
|Nuclear Medicine Radioisotopes Market Size (2023E)||US$ 8.82 Billion|
|Forecasted Market Value (2033F)||US$ 19.04 Billion|
|Global Market Growth Rate (2023 to 2033)||8% CAGR|
|No. of Pages||170 pages|
|No. of Tables||52 Tables|
|No. of Figures||56 Figures|
For oncology and treatment for cancer, therapeutic radioisotopes are replacing traditional chemotherapy procedures because they are more practical, which is further generating new opportunities in the nuclear medicine radioisotopes market. Furthermore, when compared to X-Rays and other external radiation imaging systems, radioisotopes serve as an accurate & safe alternative for patients as well as aiding doctors during diagnosis.
The technetium-99 radioisotope is expected to account for a sizable share of the global market in 2023 due to its expanding use in diagnostics.
- The World Nuclear Organization estimates that around 40 million treatments a year, or almost 80% of all nuclear procedures performed worldwide, are performed with technetium-99.
Key Takeaways from Market Study
- The global nuclear medicine radioisotopes market is expected to increase at a CAGR of 8% from 2023 to 2033.
- Germany’s market for nuclear medicine radioisotopes is predicted to expand at a CAGR of 6.5% during the projected period.
- Global sales of technetium-99m (Tc-99m) radioisotopes are expected to rise at a CAGR of 9% during the forecast period.
- Demand for thallium-201 (Tl-201) radioisotopes is predicted to expand at a CAGR of 6.5% during the next 10 years.
“North America & Europe are leading regional markets for nuclear medicine radioisotopes due to the presence of key market players,” says a Fact.MR analyst.
Get Customization on this Report for Specific Research Solutions – https://www.factmr.com/connectus/sample?flag=RC&rep_id=8311
Recent Market Developments
- Technetium-99m (Tc-99m), the most popular medical radioisotope, will be more readily available worldwide starting in March 2021 due to a collaboration between IBA (Ion Beam Applications SA) and NorthStar Medical Radioisotopes LLC.
- To commercialize and develop advanced alpha-emitting radiopharmaceutical and combination therapies for cancer therapy, Fusion Pharmaceuticals, a leading Canadian radiopharmaceutical company, announced collaboration with Anglo-Swedish pharmaceutical behemoth AstraZeneca in November 2020.
Key Companies Profiled
- Bayer AG
- Bracco Imaging SpA
- Cardinal Health, Inc.
- GE Healthcare
- Hologic, Inc.
- Lantheus Medical Imaging, Inc.
- Medtronic PLC
- NTP Radioisotopes SOC Ltd.
- Positron Corporation
- Siemens Healthineers
Segments of Nuclear Medicine Radioisotopes Industry Research
- By Radioisotope Type :
- Technetium-99m (Tc-99m)
- Thallium-201 (Tl-201)
- Gallium-67 (Ga-67)
- Iodine (I-123)
- By Application :
- By End User :
- Diagnostic Centers
- Specialty Clinics
- Education & Research Institutes
- By Region :
- North America
- Latin America
- East Asia
- South Asia & Oceania
Explore Our Safe & Secure Payment Options for Quick Buy – https://www.factmr.com/checkout/8311
More Valuable Insights on Offer
Fact.MR, in its new offering, presents an unbiased analysis of the global nuclear medicine radioisotopes market, presenting historical demand data (2018 to 2022) and forecast statistics for the period of 2023 to 2033.
The study divulges essential insights on the market on the basis of radioisotope type (technetium-99m (Tc-99m), thallium-201 (Tl-201), gallium-67 (Ga-67), iodine (I-123)), application (cardiology, oncology, neurology, lymphoma, thyroid), and end user (hospitals, diagnostic centers, specialty clinics, education & research institutes), across five major regions of the world (North America, Europe, Asia Pacific, Latin America, and MEA).
Check out more related studies published by Fact.MR Research:
Oxygen Conserving Devices Market: The global oxygen conserving devices market is surging from a US$ 1.6 billion valuation in 2022 to end up at a market valuation of US$ 4.8 million by 2032. Shipments of oxygen conserving devices are projected to increase at a stellar CAGR of 11.6% over the next ten years. The market for oxygen conserving devices in the United States is anticipated to exhibit expansion at an impressive CAGR of 10.8% owing to the presence of developed healthcare infrastructure and the high availability of different types of portable oxygen conserving devices.
Patient Lifting Equipment Market: Worldwide demand for patient lifting equipment is anticipated to increase at a high-value CAGR of 7.3% from 2022 to 2027. Currently, the global patient lifting equipment market stands at a valuation of US$ 1.5 billion and is predicted to reach US$ 2.3 billion by the end of 2027. Rising incidence of accidents resulting in severe injuries and increasing disability among the general population, especially the elderly, are expected to be prominent factors driving global sales of patient lifting equipment over the years to come.
Medical Equipment Cooling Market: The global medical equipment cooling market is currently valued at around US$ 210 million and is anticipated to expand at a CAGR of 3.6% to reach US$ 278.67 million by 2030. Demand for medical equipment cooling is expected to be high in the regions of Asia Pacific and Latin America over the next ten years.
Insulin Storage Devices Market: At present, the global insulin storage devices market enjoys a valuation of US$ 798 million and is expected to surge to US$ 1.28 billion by the end of 2027. Worldwide insulin storage device sales are expected to rise at a high CAGR of 8.1% from 2022 to 2027. Increasing prevalence of diabetes owing to poor lifestyle habits is expected to significantly drive insulin storage device usage over the years to come. Insulin monitors and insulin scanners are products that are expected to witness high demand owing to the rising prevalence of diabetes across the world.
Oncology Biosimilars Market: The market for oncology biosimilars is anticipated to surge up at an astronomical pace, registering a CAGR of 11% during the forecast period from, and 2022 to 2032. As of 2021, the market was valued at US$ 4 Billion, and is likely to rise at a Y-o-Y growth rate of 5% in 2022 to reach US$ 4.2 Billion. By the end of the forecast period, the industry is poised to reach US$ 12 Billion.
We are a trusted research partner of 80% of fortune 1000 companies across the globe. We are consistently growing in the field of market research with more than 1000 reports published every year. The dedicated team of 400-plus analysts and consultants is committed to achieving the utmost level of our client’s satisfaction.
Specialties: Competition Tracking, Customized Research, Syndicated Research, Investment Research, Social Media Research, Business Intelligence, Industry Analysis, Thought Leadership.
US Sales Office:
11140 Rockville Pike
Rockville, MD 20852
Tel: +1 (628) 251-1583
- Fluence Energy, Inc. Announces First Quarter 2023 Earnings Release Date, Conference Call and Webcast - January 27, 2023
- Lawsuit Deadline Notice: Investors who lost over $250,000 with shares of Iris Energy Limited (NASDAQ: IREN) should contact the Shareholders Foundation - January 27, 2023
- Purple City Labs Introduces OnSight, a Molecular Assay for In-house Testing of Hop Latent Viroid - January 27, 2023